ASCO-SITC Pre-Annual Meeting Seminar

Starts:  May 31, 2018 12:30 (CT)
Ends:  Jun 1, 2018 11:00 (CT)

This program has already taken place.

The ASCO Pre-Annual Meeting Seminar was created by the American Society of Clinical Oncology (ASCO), co-sponsored with the Society for Immunotherapy of Cancer (SITC). 

This seminar enabled clinical oncologists, nurses, pharmacists, and the entire medical team to effectively offer their patients additional treatment options through immunotherapy. Advances in cancer immunotherapy research are rapidly emerging, with an increasing rate of new approvals for the routine clinical use of immunotherapy agents in the clinic across a variety of cancers. The pace of progress in the field necessitates the continuing education of oncology clinicians to enable them to provide the most up-to-date and comprehensive immunotherapy-based treatment options to their patients. In addition, oncologists, nurses and pharmacists with basic knowledge related to utilizing immunotherapy in clinical practice continue to be challenged by issues related to patient selection and toxicity management.

Cancer Immunotherapy Today: Maximizing Patient Outcomes

Day 1: Thursday, May 31, 2018: 12:30 PM - 5:00 PM

12:30 p.m. 1:00 p.m.


1:00 p.m. 1:25 p.m.

Session 1: Basic Principles of Immunotherapy


Immunotherapy Basics
Mario Sznol, MD - Yale School of Medicine


Panel Question and Answer

1:25 p.m. – 2:55 p.m.

Session 2: Integrating Immunotherapy Into Clinical Practice—Changes Over the Past Year (Part 1)


Melanoma and Other Skin Cancers
Michael A. Postow, MD - Memorial Sloan Kettering Cancer Center
Question and Answer


Lung Cancer
Naiyer A. Rizvi, MD - Columbia University Medical Center
Question and Answer


Breast and Gynecologic Cancers
Leisha A. Emens, MD, PhD - The Johns Hopkins University
Question and Answer

2:55 p.m. - 3:10 p.m.


3:10 p.m. - 5:00 p.m.

Session 2: Integrating Immunotherapy Into Clinical Practice—Changes Over the Past Year (Part 2)


Gastrointestinal Cancers
Michael Morse, MD - Duke University School of Medicine
Question and Answer


Genitourinary Cancers
Neeraj Agarwal, MD - Huntsman Cancer Institute at the University of Utah
Question and Answer


Head and Neck Cancers
Robert L. Ferris, MD, PhD, FACS - University of Pittsburgh Medical Center and University of Pittsburgh Cancer Institute
Question and Answer


The Impact of Immunotherapy On A Community Practice
Alexander I. Spira, MD, PhD, FACP - Virginia Cancer Specialists Research Institute and Oncology Research
Question and Answer

Day 2: Friday, June 1, 2018: 7:00 AM - 11:00 AM

7:00 a.m. – 7:30 a.m.


7:30 a.m. – 8:15 a.m.

Session 3: Hematologic Malignancies and CAR-T Cell Therapy


Mario Sznol, MD - Yale School of Medicine

Hematologic Malignancies
John Timmerman, MDUniversity of California, Los Angeles


Clinical Application of Cell Therapies: Mechanism of Action, Efficacy, and Patient Selection
Kevin J. Curran, MD - Memorial Sloan Kettering Cancer Center


Panel Question and Answer

8:15 a.m. – 8:30 a.m.


8:30 a.m. – 10:30 a.m.

Session 4: Managing Immune-Related Adverse Events—The Challenge to Maximize the Risk/Benefit Ratio


A Case-based Panel Discussion
Mario Sznol, MD - Yale School of Medicine

Ravi A. Madan, MD – National Cancer Institute

Krista Rubin, APRN-BC - Massachusetts General Hospital
Nurse Perspective

Joachim M. Baehring, MD - Yale School of Medicine
Neurologist Perspective

Jaydira Del Rivero, MD - National Cancer Institute
Endocrinologist Perspective

Elizabeth J. Shpall, MD - The University of Texas MD Anderson Cancer Center
Cell Therapist/Benign Hematologist Perspective


10:30 a.m. 11:00 a.m.

Session 5: The Future of Immunotherapy—Novel Agents in Clinical Trials


Ravi A. Madan, MD – National Cancer Institute

New Agents in Clinical Trials: Significant Phase I-III Clinical Trial
James Gulley, MD, PhD - National Cancer Institute


Panel Question and Answer



McCormick Place
2301 S King Dr
Room S100bc
Chicago, IL 60616